National Cancer Institute at the National Institutes of Health
Bethesda, Maryland, United States
Ramaprasad Srinivasan obtained his M.D. from the Bangalore Medical College in India and then completed his Ph.D. in biomedical sciences at the University of Texas MD Anderson Cancer Center in Houston. He came to the NCI in 1999 after completing his internal medicine residency training at the University of Texas Health Science Center-Houston, to pursue a fellowship in medical oncology/hematology. After completing his fellowship, Dr. Srinivasan joined the Urologic Oncology Branch as a Staff Clinician. He is currently an Investigator and Head of the Molecular Cancer Section, Urologic Oncology Branch. Dr. Srinivasan is developing treatment strategies and clinical trials for patients with both hereditary and non-hereditary forms of kidney cancer. He is investigating a variety of newer 'targeted' agents as well as novel immunotherapy approaches, in clear cell and papillary kidney cancer, as well as hereditary kidney cancer syndromes such as von Hippel-Lindau (VHL), hereditary leiomyomatosis and renal cell cancer (HLRCC) and hereditary papillary renal cell cancer (HPRC).
Disclosure information not submitted.